{"nctId":"NCT01535053","briefTitle":"Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia","startDateStruct":{"date":"2012-06-18","type":"ACTUAL"},"conditions":["Choriocarcinoma","FIGO Stage I Gestational Trophoblastic Tumor","FIGO Stage II Gestational Trophoblastic Tumor","FIGO Stage III Gestational Trophoblastic Tumor","Hydatidiform Mole"],"count":57,"armGroups":[{"label":"Arm I (dactinomcin)","type":"EXPERIMENTAL","interventionNames":["Biological: Dactinomycin","Other: Quality-of-Life Assessment"]},{"label":"Arm II (leucovorin calcium and methotrexate)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Leucovorin Calcium","Drug: Methotrexate","Other: Quality-of-Life Assessment"]}],"interventions":[{"name":"Dactinomycin","otherNames":["Actinomycin A IV","Actinomycin C1","Actinomycin D","Actinomycin I1","Actinomycin IV","Actinomycin X 1","Actinomycin-[thr-val-pro-sar-meval]","Cosmegen","DACT","Dactinomycine","Lyovac Cosmegen","Meractinomycin"]},{"name":"Leucovorin Calcium","otherNames":["Adinepar","Calcifolin","Calcium (6S)-Folinate","Calcium Folinate","Calcium Leucovorin","Calfolex","Calinat","Cehafolin","Citofolin","Citrec","Citrovorum Factor","Cromatonbic Folinico","Dalisol","Disintox","Divical","Ecofol","Emovis","Factor, Citrovorum","Flynoken A","Folaren","Folaxin","FOLI-cell","Foliben","Folidan","Folidar","Folinac","Folinate Calcium","folinic acid","Folinic Acid Calcium Salt Pentahydrate","Folinoral","Folinvit","Foliplus","Folix","Imo","Lederfolat","Lederfolin","Leucosar","leucovorin","Rescufolin","Rescuvolin","Tonofolin","Wellcovorin"]},{"name":"Methotrexate","otherNames":["Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039"]},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who meet International Federation of Gynecology and Obstetrics (FIGO) stage I, II, or III criteria for low-risk gestational trophoblastic neoplasia (GTN): post molar GTN or choriocarcinoma (as defined below); patients may have had a second curettage but must still meet GTN criteria below:\n\n  * Post molar GTN\n\n    * For the purposes of this study, patients must have undergone evacuation of a complete or partial hydatidiform mole and then meet the criteria for GTN defined as:\n\n      * A \\< 10% decrease in the hCG level using as a reference the first value in the series of 4 values taken over a period of 3 weeks (\\> 50 mIU/ml minimum) OR\n      * A \\> 20% sustained rise in the hCG taking as a reference the first value in the series of 3 values taken over a period of 2 weeks (\\> 50 mIU/ml minimum) OR\n      * A persistently elevated hCG level a period of 6 months or more following the initial curettage (\\> 50 mIU/ml minimum)\n  * Choriocarcinoma\n\n    * Histologically proven non-metastatic choriocarcinoma OR\n    * Histologically proven metastatic choriocarcinoma if the metastatic site(s) is restricted to one (or more) of the following: vagina, parametrium, or lung\n* World Health Organization (WHO) risk score 0-6\n* Patients must be willing to practice effective contraception for the duration of the study\n* White blood cell count (WBC) \\>= 3,000 cells/mcL\n* Granulocytes \\>= 1,500/mcL\n* Platelets \\>= 100,000/mcL\n* Creatinine =\\< 2.0 mg/dcL\n* Bilirubin =\\< 1.5 x institutional normal\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\< 3 x institutional normal\n* Alkaline phosphatase =\\< 3 x institutional normal\n* Patients who have met the pre-entry requirements\n* Before enrolling a patient, the institution must verify the availability of an adequate supply of methotrexate for a full course of therapy\n* Patients must have signed an approved informed consent and authorization permitting release of personal health information\n\nExclusion Criteria:\n\n* Patients who do not have GTN\n* Patients with non-gestational choriocarcinoma\n* Patients who have previously been treated with cytotoxic chemotherapy; however, patients who received prior low-dose methotrexate for treatment of an ectopic pregnancy will be eligible for this study\n* Patients who have received prior pelvic radiation\n* Patients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT)\n* Patients with Gynecologic Oncology Group (GOG) performance status of 3 or 4\n* Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy\n* Patients whose circumstances at the time of study entry do not permit completion of the study or required follow-up\n* Patients who wish to breast-feed during treatment","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Complete Response","description":"Complete Response is defined as 3 consecutive bi-weekly values of hCG\\<5 over a minimum of 4 weeks of normal hCG values with no values greater than 5 mIU/ml","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null},{"groupId":"OG001","value":"88.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With CTCAE v4 Graded Adverse Events With Low-risk Gestational Trophoblastic Neoplasia by Arm","description":"Maximum grade of physician assessed adverse events reported during treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Post Protocol Surgical Treatment for Each Arm.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Post Protocol Multi-agent Chemotherapy Treatment for Each Arm.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Quality of Life (QOL) at Baseline","description":"Patient reported quality of life was measured with the Functional Assessment of Cancer Therapy - Generic (FACT-G). The FACT-G is a scale for assessing general QOL of cancer patients. It consists of four subscales: Physical Well Being, Functional Well Being, Social/Family Well-Being, and Emotional Well-Being. Each item in the FACT-G was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements, reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The FACT-G score is calculated as the sum of the subscale scores. The FACT-G score ranges 0-108. A larger score suggests better QOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":"2.7"},{"groupId":"OG001","value":"81.9","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Patient-reported Quality of Life (QOL) After Baseline Visit.","description":"Patient reported quality of life was measured with the Functional Assessment of Cancer Therapy - Generic (FACT-G). The FACT-G is a scale for assessing general QOL of cancer patients. It consists of four subscales: Physical Well Being, Functional Well Being, Social/Family Well-Being, and Emotional Well-Being. Each item in the FACT-G was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements, reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The FACT-G score is calculated as the sum of the subscale scores. The FACT-G score ranges 0-108. A larger score suggests better QOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":"2.3"},{"groupId":"OG001","value":"81.6","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":"3.3"},{"groupId":"OG001","value":"78.9","spread":"2.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":"2.7"},{"groupId":"OG001","value":"84.5","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":"2.9"},{"groupId":"OG001","value":"90.9","spread":"2.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":28},"commonTop":["Nausea","Fatigue","Mucositis Oral","Anemia","Constipation"]}}}